VOWST®
(fecal microbiota spores, live-brpk) capsules

VOWST is the FIRST and ONLY orally administered microbiome therapeutic to prevent *C. difficile recurrence[1,2]**

SUPERIOR PREVENTION
OF *C. DIFF* RECURRENCE VS ANTIBIOTICS ALONE

PRIMARY ENDPOINT

88% *P*<0.001

RECURRENCE FREE AT 8 WEEKS

(vs 60% of participants receiving antibiotics alone)[1,2,†]

SECONDARY ENDPOINT

79% *P*<0.001

RECURRENCE FREE AT 24 WEEKS

(vs 53% of participants receiving antibiotics alone)[1,3,‡]

GENERALLY WELL TOLERATED THROUGH 8 WEEKS[1]

- The majority of adverse reactions were mild or moderate in severity
- Most adverse reactions occurred within 10 days of starting VOWST
  - The median duration of these events was ≤5 days
- No serious adverse events were considered related to the use of VOWST

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Transmissible infectious agents: Because VOWST is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.

Potential presence of food allergens: VOWST may contain food allergens. The potential to cause adverse reactions due to food allergens is unknown.

ADVERSE REACTIONS

The most common adverse reactions (reported in ≥5% of VOWST-treated participants, and at a rate greater than placebo) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%).

To report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov/MedWatch.

DRUG INTERACTIONS

Do not administer antibacterials concurrently with VOWST.

INDICATION

VOWST is indicated to prevent the recurrence of *Clostridioides difficile* infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).

Limitation of Use: VOWST is not indicated for treatment of CDI.

Please see full Prescribing Information and Patient Information at booth #3041.

VISIT VOWST AT BOOTH #3041

Scan the QR or visit **VOWSThcp.com** to learn more

*_Clostridioides difficile (C. diff)_* infection.

†Calculated by the rate of recurrence, which was significantly lower in VOWST recipients compared to those receiving antibiotics alone—12% vs. 40%, respectively—a 0.32 relative risk (95% confidence interval [CI], 0.18, 0.58; *P*<0.001).[1,2]

‡Relative risk of 0.46 (95% CI, 0.30, 0.73).[1,3]

ECOSPOR III was a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial evaluating *C. diff* recurrence at 8 weeks; secondary endpoints at 4, 12, 24 weeks. In the intent-to-treat population, participants received VOWST or placebo after standard-of-care antibiotic treatment (vancomycin/fidaxomicin) and laxative. Those lost to follow-up, terminated prematurely, or died prior to end of study time interval counted as a recurrence. Data were rounded to the nearest whole number for presentation.[1-3]

REFERENCES: 1. VOWST. Prescribing information. Seres Therapeutics, Inc.; 2023. Accessed February 9, 2024. https://www.serestherapeutics.com/our-products/VOWST_PI.pdf **2.** Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent *Clostridioides difficile* infection. *N Engl J Med*. 2022;386:220-229. doi:10.1056/NEJMoa2106516 **3.** Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent *Clostridioides difficile* infection in a randomized clinical trial. *JAMA*. 2022;328(20):2062-2064. doi:10.1001/jama.2022.16476

Nestlé HealthScience®

SERES THERAPEUTICS